Burstein HJ, et al. - In this systematic review of randomized clinical trials from 2012 to 2018, researchers examined females with node-positive breast cancer receiving extended therapy, including aromatase inhibitor (AI) to renew the American Society of Clinical Oncology, Inc. (ASCO) clinical practice guideline on adjuvant endocrine therapy based on emerging data about the optimal span of aromatase inhibitor (AI) treatment. They noticed average benefits in absolute risk of reduction. An individualized approach to treatment duration based on considerations of risk reduction and tolerability was considered appropriate for lower-risk node-negative or limited node-positive cancers. They suggested shared decision making between clinicians and patients appropriate for decisions about extended adjuvant endocrine therapy (including discussions about the absolute privileges in breast cancer recurrence reduction, prevention of second breast cancers, and the influence of adverse outcomes of therapy).